End Colon Cancer Coast to Coast
Take action today—start a fundraiser and be part of a nationwide effort to save lives.
Research funded by Project Cure CRC
Innovation is in progress.
Funding urgent science for today’s patients
The Alliance’s Project Cure CRC continues to make global investments based on expert recommendations and areas of urgent necessity, outlined in this request for proposals. Awardees are listed below.
Funded research
Therapy for MSS disease
Raghu Kalluri, MD, PhD
Dr. Kalluri of MD Anderson Cancer Center aims to develop urgently needed therapeutic options for the 96% of colorectal cancer patients with microsatellite stable (MSS) disease.
Theranostics for BRAF mutations
H. Charles Manning, PhD
H. Charles Manning, PhD, a professor at MD Anderson Cancer Center, will lead a collaborative effort to discover the first theranostic pair for imaging and therapy for patients with CRC.
Immunotherapy for MSS disease
Peter Lee, MD
Dr. Peter Lee of City of Hope will pursue a novel combination immunotherapy to treat metastatic MSS colorectal cancer, which does not respond well to current treatments.
mRNA vaccine for CRC
Kevin Van der Jeught, PhD
Kevin Van Der Jeught, PhD, of the University of Miami, seeks to improve intratumoral mRNA vaccination strategies by targeting immune checkpoints to enhance anti-tumor immune responses.
Targeted radioimmunotherapy
Ekaterina Dadachova, PhD
Ekaterina Dadachova, PhD, of The University of Saskatchewan will investigate combining targeted radiation with immunotherapies for a novel and synergistic approach to treat advanced colorectal cancer, improving clinical outcomes.
New Drug Combinations for BRAF
Yekaterina Y. Zaytseva, PhD
Yekaterina Y. Zaytseva, PhD, of the University of Kentucky, will investigate new drug combinations to kill CRC cells with a BRAF mutation. These cells currently have a low response rate to existing treatments.
Investigating a New Protein
Ashiq Masood, MD
Dr. Masood of Indiana University is studying ProAgio, a new protein that targets cells aiding cancer's survival. This approach could improve therapies for tough-to-treat tumors.
Body Fat & CRC
Caterina Suelzu, PhD
Dr. Suelzu of Anglia Ruskin University will investigate how fat tissue impacts the growth and spread of colorectal cancer, especially in people with obesity.
Innovating with CRISPR
Julia Carnevale, MD
Dr. Carnevale of UCSF will use cutting-edge technology to target multiple genes at once, seeking to uncover weaknesses in cancer cells and boost the body’s immune response.
Stopping the Spread
David Robbins, PhD
Dr. Robbins of Georgetown University aims to target and stop the circulating tumor cells responsible for forming metastatic tumors. Success could improve mCRC survival rates.
By the numbers: Project Cure CRC
$7M
in funding allocated
19
projects supported
$100M
funding goal
Join us
Project Cure CRC seeks research proposals from early-career investigators, senior investigators, teams, startup companies, and others. We prioritize collaboration toward curative science.
Our sponsors
Related Topics
Up Next
More about the research fundTop resources
Project Cure CRC Ignites Innovation in 2025 With $10.5 Million for Research, K-Spy Debut, and Renewed RFP
Project Cure CRC by the Colorectal Cancer Alliance is driving innovation in colorectal cancer research with $10.5 million in funding, the launch of the K-SPY clinical trial, and a renewed call for groundbreaking proposals. Learn how these efforts are accelerating treatment advancements and improving patient outcomes.
Last updated
Unmet needs in CRC: Survey results offer hope
Uncover key survey findings on the unmet psychosocial and physical needs of colorectal cancer patients and survivors, and learn how the Alliance is shaping better care.
Last updated
Be heard this November: The Cancer Promise
Learn about The Cancer Promise initiative and how political candidates can pledge to support cancer research, prevention, and care policies. Make your voice heard this election.
Last updated